NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=136046&from=3 CLAS ...

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/intellia-therap ...

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=135485&from=4CLASS PERIOD ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics ...

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=134603&from=4 CLASS PERIO ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics- ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=134053&from=4 CLASS PERIOD ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics- ...

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=132973&from=4 CLASS PERIOD ...

Core Insights - Intellia Therapeutics reported Q4 earnings, focusing on advancements in three Phase 3 trials for hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR) [1] Group 1: Company Progress - The company remains pre-revenue, indicating that it has not yet generated income from its operations [1] - The report highlighted significant progress in clinical trials, which is crucial for future revenue generation [1] Group 2: Leadership and Background - The company has a leadership team with strong academic and industry backgrounds, including experience at major pharmaceutical companies and biotech startups [1]